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ROLE OF EPIGENETICS IN HEMATOPOIETIC STEM CELL 
DEVELOPMENT 
PRIYANKA DHARAMPURIYA 
ABSTRACT 
 In 2016, there were 171,550 new cases of blood cancers and over one million 
people in the United States living with one of these disorders. Bone marrow transplants 
have good outcomes, but these procedures require a donor who is a perfect match, and 
thus many patients are unable to receive treatment. It is important to find patient-derived 
treatments, such as molecules which stimulate hematopoietic stem cell (HSC) formation 
without the need for a donor. Therefore, a study was initiated to use human-induced 
pluripotent stem cell (hiPSC) technology to make a patient-derived, personalized HSC.  
Epigenetic regulators are divided into readers, writers, and erasers, and each of 
these classes has shown some effect on HSC formation. Writers add functional groups to 
deoxyribonucleic acid (DNA) and histone proteins, whereas erasers remove them. 
Readers are groups on transcription factors which interpret these changes and increase or 
decrease the recruitment of transcriptional machinery accordingly. In this study, a screen 
of 12 different candidate molecules with distinct epigenetic targets in casper zebrafish 
was conducted at 36 hours postfertilization (hpf) to reveal increases or decreases in 
definitive HSC development. The two writer molecules, C646 (histone acetyltransferase, 
or HAT, inhibitor) and OICR9249 (WDR5 inhibitor), and the two eraser molecules, Ex-
527 (Sirt1 inhibitor) and JIB-04 (bromodomain inhibitor), showed varying degrees of 
increasing HSC formation. Of these molecules, C646 created the most significant 
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increase and was further tested in the zebrafish at 48 and 72 hpf and in a murine model 
using ex vivo technique and a colony-forming unit (CFU) assay. In contrast to these 
results, the two eraser molecules, entinostat (class I histone deacetylase, or HDAC, 
inhibitor) and vorinostat (general HDAC inhibitor), were found to decrease HSC 
formation in zebrafish. The overall findings of this study provide insight into specific 
epigenetic regulators in HSC development and identify particular epigenetic markers that 
could regulate HSC formation from endothelial cells. This discovery will be a stepping 
stone in utilizing patient-derived hemogenic endothelial cells as a novel source of bone 
marrow-independent HSCs to treat patients with leukemia, lymphoma, and bone marrow 
cancers. 
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INTRODUCTION 
The leukemia and lymphoma society reports that 171,550 new diagnoses of blood 
cancers were made in 2016, and over one million people in the United States live with 
one of these disorders (National Cancer Institute). Blood disorders can range from 
anemia (red blood cell or hemoglobin deficiency) to bleeding disorders such as 
hemophilia and blood cancers such as leukemia, lymphoma, and myeloma. Bone marrow 
transplants have proven a successful treatment for many patients, but these procedures 
require a donor who is a perfect match for the recipient, and consequently, many patients 
are unable to receive treatment. Because of this issue, it is important to be able to find 
new, patient-derived treatments, such as molecules which may stimulate hematopoietic 
stem cell (HSC) formation without a donor. Therefore, a study was initiated to use 
human-induced pluripotent stem cell (hiPSC) technology to make a patient-derived, 
personalized HSC.  
 Blood forms in three distinct lineages—the myeloid, erythroid, and lymphoid 
lineages. Hematopoiesis, the formation of these cellular components, is multilineage and 
contains points of possible regulation and dysregulation, including epigenetic changes. 
Epigenetic molecules (described later in this section) have been used in treatment and 
may also be used in the treatment of blood disorders.  
All cellular blood components arise from HSCs, which both self-renew and 
differentiate into blood lineages. In the adult, HSCs reside in bone marrow (Clapes, 
2012).  The development of embryonic hematopoietic stem cells occurs at different sites 
depending on the developmental period. In this study, the cell-intrinsic and cell-extrinsic 
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factors regulating hematopoiesis will be addressed, as well as the role of epigenetics in 
the development of HSCs. This research was done through an epigenetic candidate 
molecule screen in the zebrafish and the mouse to demonstrate the changes caused by the 
epigenetic molecules and the roles of their targets.  
Sites of Hematopoietic Stem Cell (HSC) Development 
Multipotent hematopoietic stem cells require a specific microenvironment, the 
hematopoietic niche, which originates in the yolk sac of the developing embryo through 
formation of blood islands and then migrates to the embryo itself. In mice, after HSC 
formation in the yolk sac at embryonic day (E) (Figure 1, E7.5), the HSCs form in the 
para-aortic splanchnopleura (P-Sp)/aorta-gonad-mesonephros (AGM) and placenta region 
around E9.5 (Hu & Shilatifard, 2016). They then migrate to the fetal liver, where they 
reside from midgestation to late gestation (Medivinsky et al, 1993). At this point, the 
HSCs migrate to their adult site, the bone marrow.  
Primitive Hematopoiesis and the Yolk Sac 
Hematopoiesis is defined by two stages, primitive and definitive (Figure 1). 
Primitive hematopoiesis originates at “blood islands” which form from the mesoderm in 
the yolk sac (Fercowiz et al, 2003) at E7.10 in the murine embryo. The cells differentiate 
into primitive erythroblasts and the cells of the outer layer differentiate into endothelial 
cells. These cells originate in the yolk sac but mature in the bloodstream (Yoder, 2002). 
The hemangioblast theory proposes that HSCs and endothelial cells arise from a common 
progenitor. This is supported by the construction of single-cell resolution fate maps of the 
zebrafish by Vogeli and colleagues (2006) but remains a source of debate. HSCs and 
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endothelial cells contain some of the same surface markers, supporting the theory that 
they may share a precursor. 
 
Figure 1: Primitive and definitive hematopoiesis. HSCs arise by Runx1 and c-Myb 
independent primitive hematopoiesis or by definitive hematopoiesis. Each cell line arises 
from a common mesodermal origin, which branches into the primitive wave and the 
definitive wave. The primitive progenitor cells do not share an origin with endothelium of 
the yolk sac blood islands. In the definitive hematopoiesis wave, endothelium becomes 
HSCs through the Runx1 pathway. EMPs and HSCs express c-Myb, but only HSCs are c-
Myb dependent. EMP-derived hematopoiesis creates  erythrocytes and  temporary 
myeloid cells, which are replaced later by HSC-derived myeloid cells. E = embryonic 
day; EMP = erythroid/myeloid progenitor; HSC = hematopoietic stem cell; Myb = 
myeloblastosis; RUNX = runt-related transcription factor; YS = yolk sac. (Dzierzak & 
Speck, 2008)  
 
Definitive Hematopoiesis 
Definitive hematopoiesis is marked by the emergence of pluripotent 
hematopoietic stem cells which can both self-renew and differentiate into erythroid, 
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myeloid, and lymphoid lineages (de Brujn et al, 2000). The erythroid lineage develops 
into reticulocytes, which later become mature, oxygen-carrying red blood cells. The 
myeloid lineage includes granulocytes, megakaryocytes, and macrophages, whereas the 
lymphoid lineages forms the cells of the adaptive immune system(Bertrand et al, 2007). 
The first definitive HSCs in the mammalian embryo are located in the AGM 
region(Dzierzak & Speck, 2008). These cells are both self-renewing and capable of 
differentiation. HSCs may have short-or long-term renewing capacity and can replenish 
all blood cell types. The self-renewal of these HSCs occurs in the hematopoietic niche of 
the adult. Thus, the microenvironment of this niche is of great importance in 
understanding how hematopoiesis is regulated.  Through both cell culture and model 
organisms including the chick, the mouse, and the zebrafish, the regulation of HSC 
development has been shown to be controlled by factors like developmental history, 
tropic effects, and biophysical cues. 
Cell-Intrinsic Regulators of Hematopoiesis   
HSC self-renewal is driven both by cell-specific intrinsic regulators and cell-
extrinsic regulators. Cytokines and other molecules initiate pathways which lead to the 
downstream activation of transcription factors (Zape and Zovein, 2011). These 
transcription factors control the cellular decisions which determine the fate of 
differentiating cells. Thus, the presence or absence of these transcription factors may 
illuminate whether hematopoiesis is occurring, and whether it is primitive or definitive.  
The specification of blood lineages involves many regulatory signals and 
transcription factors such as c-Myb, Runx1, Lmo2, and Ikaros. It is believed that the  T-
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cell acute lymphocytic leukemia 1 (TAL1) and the LIM domain only 2 (LMO2) genes are 
implicated in the hemangioblast(Jong and Zon, 2005), whereas runx1 and c-myb are used 
as the first definitive markers of hematopoiesis in the zebrafish model (Table 1). 
Table 1: Different Stages of Hematopoiesis and Differentiation Indicated by 
Different Marker Genes. Table adapted from de Jong and Zon (2005.)  
Cell Type Marker Genes Expressed 
Primitive Progenitor Cell scl, flila, gata2, bhex, lmo2, tifly 
Definitive HSC c-myb, cbfB, ikaros, runx1 
Myeloid lineage precursors pu.1 
Neutrophil mpo 
Eosinophil None known 
Monocyte/Macrophage l-plastin, draculin, fms 
Erythrocyte gata-1, globin, alas2, B-spectrin, fch, urod, dmt1 
Lymphocyte ikaros, rag-1, rag-2, lck 
 
Notch Pathway 
Maillard et al (2014) reported that Notch is necessary for the formation of HSCs 
in vitro but not in vivo with mouse xenograft. Notch signaling regulates hematopoiesis in 
vertebrates and expanded cord blood progenitor cells in mice (Delaney et al, 2010). 
Notch is a highly conserved signaling pathway that is vital in cell differentiation (Bigas 
and Espinosa, 2014) and depends on cell-cell interactions. Notch promotes T-cell 
differentiation in the adult but also other blood lineages, which are still being identified. 
The Notch receptor itself is a single-pass transmembrane receptor that may be activated 
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by different ligands (Bigas and Espinosa, 2014). The resulting signal transduction leads 
to transcription regulation downstream, particularly of the Hes and Hes-related (Hrt) 
family of genes. These genes code for proteins that generally function as inhibitors of cell 
differentiation. In the embryo, Notch1 is required for the formation of HSCs. Notch is 
responsible for or involved in a variety of functions in HSC differentiation.  
Runx1 
The transcription factors Gata2, Scl, and Runx1 are directly implicated in   
endothelial-to-hematopoietic transition (EHT). Runt-related transcription factor 1 
(RUNX1) is a transcription factor responsible for regulating the differentiation of 
hematopoietic stem cells into mature blood cells. Mutations, especially chromosomal 
translocations, are implicated in leukemia (Asou, 2003). Recently, Runx1 was shown to 
repress the erythroid gene expression program during the formation of 
megakaryocytes(Kuvardina et al, 2015).   
HDAC 
Histone deacetylase (HDAC) was shown to inhibit human hematopoietic stem cell 
expansion in ex vivo culture (Broxmeyer, 2014). Broxmeyer found that the inhibition of 
HDAC improved the ex vivo expansion of HSCs and increased the amount of 
engraftment to the mouse model. Shah and colleagues (2013) employed the class I 
selective HDAC inhibitor, valproic acid (VPA), during gastrulation in the Xenopus 
tadpole. They found that although VPA halted red blood cell (RBC) development, it did 
not affect the development of other tissues from the mesoderm, including the myeloid 
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and lymphoid lineages of hematopoiesis. These effects were replicated using a pan-
HDAC inhibitor as well but not by a non-HDAC inhibitor that was structurally similar to 
VPA.  
Cell-Extrinsic Regulators of Hematopoiesis 
The hematopoietic niche offers a complex environment that supports stem cell 
function by providing cytokines, growth factors, oxygen tension, and nutrients (Kosan 
and Godmann, 2015). Shear stress has also been well established as an activator of the 
Runx1 pathway. The level of shear stress changes during development as a result of 
factors such as blood velocity, presence of carbon dioxide (CO2), vessel length, and 
radius. For erythroblasts in early circulation, higher viscosity causes higher shear stress, 
which upregulates Runx1 and leads to HSC formation. Shear stress may also be different 
depending on the location in the bone marrow (Lee et al., 2013). Other cell-extrinsic 
factors include gut microbiota, which were shown to sustain hematopoiesis (Theilgard, 
2017). Compounds in the gut microbiota stimulate lymphocytes, macrophages, and 
dendritic cells in the lamina propia of the gastrointestinal (GI) tract. In this way, they 
maintain tonic activity of HSCs and hematopoietic stem and progenitor cells (HSPCs), 
promoting both hematopoiesis and the innate immune system (Theilgard, 2017). 
 
Classes of Epigenetic Transcription Factors 
The term epigenetics, meaning “on top of” or “around” genetics, concerns 
changes in phenotype without changes in genotype—that is, it alters gene expression 
without altering the genes themselves (Allis & Jenuwein, 2015). As a result, although 
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every cell in the body contains identical deoxyribonucleic acid (DNA), each tissue 
produces proteins according to its specific needs.  Allis et al. (2015) explained that this is 
accomplished through a variety of removable molecular tags, which recruit or block 
different transcription factors from binding to DNA and control whether the gene is 
expressed.  The transcription factors described previously, such as RUNX1 and SCL, are 
thus subject to epigenetic control. 
Molecular tags regulate epigenetic control by taking advantage of the unique 
chemical nature of DNA (Allis et al., 2015). The sugar-phosphate backbone of DNA 
gives it a negative charge, which allows the DNA to tightly wrap around histone 
octamers (Figure 2).Every nucleosome is an octamer of four histone subunits—H2A, 
H2B, H3 and H4 (Musselman et al., 2012).  Histone proteins are rich in lysine residues at 
the H3 and H4 subunits and have a positive charge, causing the DNA to bind to the 
protein and form the nucleosome. This tight wrapping around the histone, known as 
“heterochromatin,” is associated with a lowered rate of transcription. The close adherence 
of the DNA to the histone does not allow transcription factors to bind to DNA and recruit 
RNA polymerase to begin the process of transcription. By contrast, euchromatin (or 
“true” chromatin) describes a state of DNA loosely associated with the histone proteins, 
allowing proteins to dock and transcription to occur. These two states are the cornerstone 
of epigenetic control and are regulated by tags, either on the DNA itself or on the 
histones (Figure 2). Epigenetic modifiers may be classified as writers, erasers, or readers. 
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Figure 2. Epigenetic tags can be applied to either DNA or histones. DNA methylation 
at CpG islands and histone modifications affect the “closed” or “open” state of 
chromatin. DNA = deoxyribonucleic acid; CpG = cytosine (C)-guanine (G) sequence 
(Sun et al., 2013).  
Writers 
Due to their wide variety of applications, epigenetic writers make promising drug 
targets. The epigenetic writers targeted by the drugs in this study are C646, 5-azacytidine, 
A366, UNC0638, and cyproheptadine. 
Writers are a class of epigenetic modifiers which alter the structure of DNA or 
histones by adding a molecule. Major writers include histone acetyltransferases (HATs), 
histone methyltransferases (HMTs), and kinases. These enzymes insert epigenetic 
markers on amino acid residues (mainly lysine) on histone tails, although HMTs can act 
on either arginine or lysine(Wang et al, 2001). Histone lysine methylation is not highly 
reversible and may involve the transfer of one, two, or three methyl groups, depending on 
the enzyme (Allis et al., 2015). Histone arginine residues can also undergo methylation 
by protein arginine methyltransferases (PRMTs).  
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In DNA methylation, the methyl group is added to a cytosine residue in a CpG 
island, or repeated cytosine-guanine sequence. DNA methylation, especially that of 5-
methylcytosine (5mC), was established in the 1970s. This discovery gave rise to the very 
first pharmaceutical epigenetic drug, 5-azacytidine, which blocks DNA methylation. This 
drug is used in the treatment of myelodysplastic syndrome and occasionally in the 
treatment of acute myeloid leukemia. As a chemical analogue of cytosine, 5-azacytidine 
acts by inhibiting DNA methyltransferase (DNMT), which causes hypomethylation of 
DNA. This drug causes anemia, neutropenia, and thrombocytopenia at higher doses.  
The purification and cloning of the DNA methyltransferase DNMT1 and the 
generation and analysis of DNMT1-mutant mice were crucial advances in the field. 
DNMT1 is a methyltransferase which establishes and regulates methylated cytosine 
residues in a tissue-specific manner (Allis et al., 2015). DNMT1 has critical roles in 
hematopoiesis. The DNMT family of enzymes catalyzes the methylation of CpG islands 
or, in the case of DNMT1, maintains existing methylation. Dnmt1-deficient HSCs have 
been shown to suffer impaired self-renewal and increased (unrepressed) expression of 
myeloerythroid regulators, which leads to a skewed commitment to this line in these 
mice. Dnmt1 is thus especially required for HSC self-renewal (Trowbridge et al, 2009) in 
the myeloid line and has been shown to control a number of the lineages.  In 
hematological malignancies, the distribution of methylated cytosines was shown to be 
disrupted (Hu & Shilatifard, 2016).   
Histone lysine residues can also be acetylated.  The most conserved 
acetyltransferase is likely histone acetyltransferase (HAT), which has been implicated in 
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hematopoiesis. For example, the HAT p300 targets the gene c-Myb and limits the 
proliferation of HSCs. In hematological malignancies, p300 targets Notch3 and promotes 
its uncontrolled proliferation (Sun et al., 2015). 
HAT functions by transferring an acetyl group from acetyl-COA to a histone 
lysine residue, and protein acetylation has been shown to regulate HSC self-renewal and 
differentiation. The HAT p300 was found to block proliferation of c-Myb (Sun et al., 
2015). HAT inhibitors, specifically the plant-based HAT inhibitor Garcinol, have been 
shown to increase the ex vivo expansion of human HSCs (Nishino et al., 2011). HAT 
inhibitors also may have some clinical uses. Giotopoulos et al. (2016) reported that C646 
acts as a highly selective inhibitor of CREB (cyclic adenosine monophosphate, or cAMP, 
response element-binding protein)-binding protein (CBP) and its paralogue EP300 
(p300). These enzymes are both key epigenetic factors with lysine acetyltransferase 
(KAT) activity that can acetylate histones, among other proteins. Giotopoulos and 
colleagues (2016) used CBP/p300 as a therapeutic target in acute myeloid leukemia 
(AML). They reported that Cbp was required for immortalization of AML cells as well as 
induction and maintenance of AML in vivo. Their results in the murine model and in 
human cell lines indicated that acetylation of both histone and nonhistone proteins by 
CBP and p300 possibly facilitate leukemogenesis (Giotopoulos et al., 2016). Due to this 
link to leukemogenesis, HAT may have a role in the proliferation of the myeloid and 
lymphoid lineages.  
Other epigenetic writers include enzymes which phosphorylate histones. For 
example, JAK3 disrupts the binding of heterochromatin protein HP1a to chromatin, 
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which leads to increased accessibility of DNA and transcription of LMO2, an oncogene 
implicated in HSC development (Goldie et al, 2008).  
One of the drugs of this study, C646, is a HAT p300  inhibitor which has been 
shown to induce apoptosis in AML1-ETO (Eight-Twenty One oncoprotein)-positive 
AML cells (Gao et al., 2013)This class of drugs has been tested for cancer therapy, most 
recently as a blocker of neuroblastoma cell growth in vivo by causing hypoacetylation 
(Gajer et al., 2015). The second drug of this study, A366, is a potent inhibitor of G9a, a 
histone lysine methyltransferase responsible for the dimethylation of lysine 9 on histone 
H3 (H3K9me2) (Sweis et. al, 2014). The third drug, UNC0638, another G9a inhibitor, 
reactivated G9a-silenced genes in mouse embryonic stem cells (Vedadi et al., 2011). 
Treatment with UNC0638 reduced global H3K9me2 levels. Finally, the drug 
cyproheptadine, used in the treatment of allergies, was also identified as an inhibitor of 
lysine methyltransferase SET7/9. 
Erasers.  
Erasers remove groups like acetyl, methyl, and phosphate groups from DNA, 
returning the structure to its original state. In some ways, erasers can be considered to 
have the opposite effect of writers. This is essential for the reversibility of epigenetic 
modifications. Examples of erasers include histone lysine demethylases (KDMs) and 
histone deacetylases (HDACs). HDAC1 is a downstream hematopoietic inhibitor of 
Notch and possibly a regulator of Runx1 (Zape and Zovein, 2011). HDAC mutants 
demonstrated an absence of HSCs similar to that of Notch signaling (Burns et al., 2009). 
Another important class of erasers are the sirtuins, which have HDAC activity.  
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Two HDAC inhibitors are addressed in this study, Vorinostat and Entinostat. 
Vorinostat is commercially available and has been shown to inhibit the proliferation and 
induced apoptosis of cells expressing the JAK2V617F mutation by blockage of 
phosphorylation at several key sites. The JAK2V617F mutation is present in many 
patients with Philadelphia (Ph)-negative myeloproliferative neoplasms (Akada et al., 
2010). This result suggests that vorinostat may be useful for the treatment of 
polycythemia vera, a blood cancer characterized by slow overproduction of red blood 
cells (Akada et al., 2010) 
         Entinostat, a class I HDAC inhibitor, has been proposed as a therapy in the 
treatment of breast cancer (Damaskos et al., 2017). HDAC has been shown to regulate 
cell fate choices during the process of differentiation into the myeloid line in CD34+ cells 
derived from umbilical cord blood (Bartels et al., 2010). Entinostat has been used with 5-
azacytidine, a DNA methyltransferase (DNMT) inhibitor, in cancer therapies.(Fandy et 
al., 2009). 
Like HDACs, sirtuins remove acetyl groups from lysine residues (Howitz, 2015). 
Epigenetic changes in the sirtuin family, like SIRT1, may counteract some of the effects 
of aging and type II diabetes (Milne et al., 2007).  
The selective drug Ex-527 is a Sirt1 inhibitor. It is a potent and highly selective 
nicotinamide adenine dinucleotide (NAD)-dependent deacetylase sirtuin-1 (Sirt1) 
inhibitor. SIRT1 is a class III histone deacetylase (Moon et al., 2013). Ex-527 functions 
as a protein deacetylase that contributes to cellular longevity (Sinclair et al, 2006). Ex-
527, or selisistat, was found to be a well-tolerated therapy of acetylation-related 
	 14	
pathologies of Huntington’s disease (Süssmuth et al., 2015). In this treatment, Ex-527 
worked better than a generalized HDAC because of its specificity. Additionally, Ex-527 
did not block the HDAC activity of Sirt1, making it useful to study as a non-HDAC 
eraser protein.  
Nicotinamide (NAM), a Sirt1 inhibitor, inhibits differentiation and helps 
expansion of hematopoietic progenitor cells by increasing homing to the bone marrow 
and increasing the amount of engraftment in ex vivo expanded CD34+ cells harvested 
from cord blood and cultured with cytokines (Peled et al., 2004). CD34+ cells cultured 
with NAM were found to home to the bone marrow with higher efficacy than the control. 
In the same study, Ex-527 was shown to inhibit differentiation, suggesting that SIRT1 
contributes to the regulation of HSCs (Peled et al., 2004). Ex-527 was also shown to 
improve survival in a lethal mouse model of cecal ligation and puncture (CLP)-sepsis 
(Zhao et al., 2014). In addition, Ex-527 raised levels of cytokines in the blood and 
peritoneal fluid of these mice. The selective inhibition of SIRT1 also greatly increased 
fibrin cross-linkage and platelet function and decreased bone marrow atrophy. However, 
later studies indicated no difference in Sirt1-/- mice and wild-type mice in terms of 
primitive HSC populations (Leko et al., 2012).  
Clinically, the three HDAC inhibitors addressed in this study—vorinostat, 
entinostat, and Ex-527—have varying therapeutic uses in different cancers. Entinostat is 
useful as a cancer therapy because it utilizes both caspase-dependent and caspase-
independent pathways to enhance the tumor-fighting capabilities of chemotherapy agents 
and proteasome inhibitors in non-Hodgkin’s lymphoma (NHL) cells (Frys et al., 2015). 
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Vorinostat, on the other hand, functions by binding to the binding site of HDAC and 
acting as a zinc-chelating agent at the active site (Mann et al., 2007). This expands the 
accessibility of the transcription factors needed to induce cell differentiation (Richon, 
2006). Vorinostat has been used in the treatment of Sezary syndrome and other 
lymphomas (Cuneo and Castoldi, 2005). Ex-527 works through stabilization of a closed 
enzyme complex applying the (NAD+)-dependent deacylation mechanism of the sirtuin 
family (Gertz et al., 2013).   
Readers 
Readers are regions of molecules like transcription factors which have the ability 
to bind and recognize an epigenetic modification. These regions include bromodomains, 
chromodomains, and Tudor domains. Two of the molecules in this study are 
bromodomain inhibitors. De Larrea et al. (2016) found that the obstruction of the 
bromodomain of bromodomain and extra-terminal (BET) proteins augments the 
inhibition of Ikaros proteins in lenalidomide therapy in cell culture and in mice. Readers 
recognize post-translational modifications (PTMs) and recruit molecular machinery to 
initiate transcription and translation. Histones are capable of a wide variety of PTMs, 
especially in the histone tail,  whereas DNA can only be methylated. The most widely 
characterized PTM is lysine methylation, which has many readers, including theTudor 
domain, the WD40 domain, and the zinc finger. Other readers may read the methyllysine 
(Kme) region or recognize arginine methylation (Musselman et al., 2012).  
UNC1215 is a bromodomain inhibitor of the reader  class of epigenetic molecules 
which has been shown to have some effects on hematopoietic stem cell development by 
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modulating protein-protein interaction through lysine residues (James et al., 2013). 
UNC1215 is a potent, selective probe for the Kme regions of L3MBTL3, a member of 
the malignant brain tumor (MBT) family of chromatin-acting transcriptional repressors 
(James et al., 2013). In particular, Roe et al. (2015) reported that BET domain inhibition 
was shown to suppress hematopoietic transcription factors (PU.1, FLI1, ERG, C/EBPα, 
C/EBPβ, and MYB) in acute myeloid leukemia (AML). Roe and colleagues (2015) 
proposed that these transcription factors work with the HAT activity of the p300/CBP 
complex to promote transcriptional activation by facilitating the recruitment of BET 
protein BRD4. This mechanism suggests a potential pathway for bromodomain-
modulated changes to HSC expression.  
 
Figure 3. Readers, writers, and erasers modify expression of genes through different 
mechanisms. Prominent classes of each category are listed in the figure. DNA = 
deoxyribonucleic acid; HAT = histone acetyltransferase; HDAC = histone deacetylase; 
HMT = histone methyltransferase; KDM = histone lysine demethylase; PRMT = protein 
arginine methyltransferase. (Falkenberg et al., 2014) 
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Role of Epigenetics in Hematopoietic Stem Cell Development 
A number of epigenetic targets have been established as regulators in 
hematopoiesis (Sashida and Iwama, 2012). Many of these are highly conserved, common 
classes of molecules. Numerous transcription factors and epigenetic modifiers are 
involved in the maintenance of the hematopoietic niche (Kosan and Godmann, 2015). 
The human adult has only lineage-restricted hematopoietic stem cells, and each lineage 
contains a unique set of epigenetic marks. In particular, histone methylation appears 
critical in cell fate decisions. Various types of histone and DNA methylases are involved 
in different aspects of epigenetic control, and considerably more remains to be discovered 
about their role in HSC development.  
Table 2. Representative Epigenetic Genes Regulating Murine Hematopoiesis and 
Mutated in Human Hematological Malignancies 
 
Table from Sashida and Iwama (2012). 
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METHODS 
 
Study Design 
The goal of this study was to identify new epigenetic molecules that regulate fetal 
development of HSCs.  Twelve different molecules from all three classes of histone 
modifiers and effectors (readers, writers, and erasers) were selected and analyzed for their 
ability to stimulate HSC formation using in vivo models (Table 3). The molecules were 
first tested in zebrafish, and the most promising candidates were further analyzed in a 
mouse model.  
  
Table 3. Candidate Molecules and Their Classes : All molecules were obtained from 
Cayman Chemical Company (Ann Arbor, MI, USA). Molecular candidates for reader, 
writer, and eraser classes were selected based on their epigenetic targets. Doses in the 
zebrafish (zf) model were optimized based on the IC50 in cell lines and modified for the 
mouse (m) model. T = toxicity; IC50 = concentration where the response is reduced by 
half. 
 
Histone Modifiers 
and Effectors 
 
Epigenetic Target Dose 
Readers 
  
UNC1215 Bromodomains 1 µM (zf) 
 
I-BET151 Bromodomains 1µM (zf) (T) 
Writers 
  
C646 Histone acetyltransferase (HAT) 1.6 µM (zf) 
1.6 µM (m) 
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Table 3. Candidate Molecules and Their Classes (Continued)  
Histone Modifiers 
and Effectors 
 
Epigenetic Target Dose 
5-Azacytidine DNA methyltransferase (DNMT) 5 µM (zf) (T) 
 
A366 G9aHistone methyltransferase 
(G9a) 
1 µM (zf) 
UNC0638 G9aHistone methyltransferase 
(G9a) 
10 µM (zf) 
 
Cyproheptadine SET Domain-Containing Lysine 
Methyltransferase 7/9 
(Set 7/9) 
0.25 µM (zf) (T) 
 
OICR9429 WD repeat-containing protein 5 
(WDR5) 
1 µM (zf) 
 
Erasers   
Vorinostat 
Histone deacetylase (HDAC) 10 µM (zf) 
 
Entinostat HDAC (Class I) 1 µM (zf) 
 
Ex-527 NAD-dependent deacetylase sirtuin-1 
(Sirt1) 
50 µM (zf) 
 
JIB-04 Jumonji family (JmJ) 
 
 
0.1 µM (zf) 
   
 
Animal Models 
All procedures were approved by the animal care and use committee of Brigham 
and Women’s Hospital (Boston, MA, USA) and Boston Children’s Hospital (Boston, 
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MA, USA). The zebrafish was chosen as a discovery model because of its rapid 
development, its ability to produce large clutches of offspring at the break of daylight, 
and its similarity (70%) to the human genome (Howe et al., 2013). Two genetically 
modified zebrafish strains were used, casper and cd41:eGFPxFlk1MCherry . Zebrafish 
of casper background were translucent and did not need to be bleached prior to analysis 
of HSC formation. The cd41:eGFPxFlk1MCherry line contained bioluminescent material 
which allowed for the observation of HSC formation in real time (Avagyan and Zon, 
2016). Mice from the C57BL/6J inbred strain were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). 
Zebrafish Maintenance and Breeding 
Zebrafish were maintained in an aqueous environment at 28 ºC in controlled 
humidity. The lights in the facility were switched on at 8 a.m. and shut off at 10 p.m. 
daily to provide the best approximation of daylight hours. Zebrafish were used for 
breeding between the onset of adulthood and the age of approximately 1.5 years, after 
which they were deemed too old to produce enough healthy embryos for 
experimentation. On the night before embryo collection, pairs of male and female fish 
were placed in breeding tanks with diagonal plastic dividers. After the onset of light the 
next morning, the dividers were pulled, and the fish were allowed to mate. Embryos were 
collected, and approximately 200 embryos were transferred into a 100 × 20 mm Petri dish 
with 25 mL of E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM 
MgSO4) buffered with 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES). Embryos were maintained in an incubator at 28 ºC for the first 24 hours. After 
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the clutch was cleaned by removing dead embryos , the E3 media was changed and the 
dishes were kept either at 22 ºC for the next 24 hours to obtain embryos at the 
developmental stage of 36 hours postfertilization (hpf), or at 28 ºC for the next 24, 48, or 
72 hours to obtain embryos at the stage of 48, 72, or 96 hpf, respectively.  
Administration of Epigenetic Molecules to Zebrafish 
Zebrafish embryos were used to examine the ability of epigenetic molecules to 
modulate the formation of HSCs. Candidate molecules (Cayman Chemical Company, 
Ann Arbor, MI, USA) were first dissolved in dimethyl sulfoxide (DMSO) or 
dimethylformamide (DMF) and further diluted in E3 media to the assay concentration 
before use (Table 3). Molecules were administered approximately one hour 
postfertilization to embryos at a 4-cell stage. Control groups were treated with 0.1% 
DMSO. The viability of embryos was monitored daily, and the molecules were re-
administered every 24 hours.  The embryos were collected for analysis after 36, 48, and 
72 hours postfertilization.  
Zebrafish Embryo Fixation 
Collected embryos were fixed for whole-mount in situ hybridization (WISH) or o-
dianisidine staining. Before fixation at 36 hpf, embryos were enzymatically 
dechorionated. The chorion was subsequently digested by incubating the embryos with 3-
4 drops of 2 µg/mL pronase (Roche Diagnostics Corporation, Indianapolis, IN, USA) for 
4 minutes at room temperature (RT). The embryos were then fixed with 4% 
paraformaldehyde (PFA) overnight at 4 ºC with agitation.  
RNA Probe Synthesis 
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For WISH, antisense RNA probes were synthesized from linearized and purified 
plasmids. First, bacteria were transformed on ampicillin-resistant Lysogeny broth (LB) 
agar plates to incorporate the target gene. This was done by mixing the DNA in a tube 
with the competent cells and incubating the mixture on ice. The plates were then heat-
shocked with an open flame and placed in LB media with 100  × 20 mm Petri dishes and 
left overnight to express the appropriate antibiotic.  
In the second step, the plasmids were linearized using a restriction digest kit 
(QIAGEN Inc., Germantown, MD, USA) with the restriction enzyme EcoRI. The DNA 
was combined with restriction enzyme EcoRI and deionized water and incubated for one 
hour at 37 ºC. The DNA was then ligated using vector DNA, insert DNA, ligase buffer, 
and DNA ligase with water, followed by incubation at 4 ºC overnight. 
In the third step, the plasmids were purified using a QIAGEN midiprep kit. An 
individual colony was picked from the streaked selective plate and inoculated with 2–5 
mL LB medium with ampicillin. The colony was incubated with agitation at 37 ºC 
overnight. This starter culture was diluted to 1/1000 in selective LB medium, and the 
bacterial cells were harvested by centrifugation at 6000 x g for 15 minutes at 4 ºC. The 
bacterial pellet was resuspended in buffer and incubated at RT for 5 minutes in a second 
buffer after vigorous shaking. A third buffer was added, and the solution was 
immediately mixed in a thorough manner and incubated on ice for 15 minutes. The 
solution was centrifuged at ≥20,000 x g for 30 minutes at 4 °C. The supernatant 
containing plasmid DNA was removed immediately and centrifuged again for 15 minutes 
and removed. The supernatant was added to the provided QIAGEN-tip and allowed to 
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enter the resin by gravity. The QIAGEN-tip was then washed, and the DNA was eluted 
with buffer. The eluted DNA was precipitated by adding 3.5 mL isopropanol, mixing, 
centrifuging immediately at ≥15,000 x g for 30 minutes at 4 °C, and decanting the 
supernatant. The DNA pellet was then washed with 70% ethanol and centrifuged at 
≥15,000 x g for 10 minutes. The supernatant was decanted, and the pellet was allowed to 
air-dry before being redissolved in buffer. Samples from different steps of the 
purification procedure were analyzed using an agarose gel.  
Finally, RNA probes were made from the linearized and purified plasmid. The 
plasmid was incubated at 37 ºC for two hours with 1 µL of RNAse-free DNAse. After the 
addition of 80 µL of RNAse-free water, the solution was incubated at 37 ºC for 30 
minutes. The solution was then mixed with 10 µL of 3 M sodium acetate and 250 µL of 
100% ethanol and incubated at -20 ºC overnight. Following incubation, the solution was 
spun down, and the supernatant was removed, leaving the pellet and remaining 
supernatant in the tube. The supernatant was allowed to evaporate, and the pellet was 
dissolved in RNAse-free deionized water. As a final step, an agarose gel was run to 
ensure that probes of the appropriate base pair lengths were present and free of any 
contamination.  
Whole-Mount In Situ Hybridization (WISH) 
The WISH technique was used to analyze RNA expression in zebrafish embryos 
(Figure 5). Combination probes using markers c-myb/runx1 and lmo2/ikaros were used at 
36 hpf to detect HSCs. At later time points, globin (48 hpf), mpo (48 hpf), and rag1 (72 
hpf) were used to analyze hemoglobin, monocytes, and lymphocytes, respectively. After 
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overnight PFA fixation, embryos were washed four times with PBT (1X phosphate-
buffered saline (PBS), 0.1% Tween-20) for 5 minutes. Next, embryos were permeabilized 
with 10 µL/mL proteinase K (Roche Diagnostics Corporation) at RT for 8 minutes (36 
hpf), 11 minutes (48 hpf), or 12 minutes (72 hpf) to allow RNA probes to penetrate. 
Proteinase K digestion was stopped by incubating the embryos with 4% PFA for one 
hour. After the embryos were washed four times, they were pre-hybridized in Hyb-, a 
50% formamide buffer containing SSCT, Tween-20 (saline-sodium citrate (SSC) buffer 
and Tween-20) and placed in a rotating oven at 68 ºC for four hours. The Hyb- was then 
replaced with a hybridization (Hyb+) solution containing Hyb-, tRNA, and heparin with 
digoxigenin-labeled antisense RNA probes for overnight hybridization at 68 ºC.  
The following day, embryos were washed using 15-minute duration sequential 
incubations in 2:1, 1:1, and 1:2 Hyb-/SSCT at 68 ºC.  Next, the embryos were washed 
twice with SSCT for 30 minutes at 68 ºC. In the second wash, the temperature was 
gradually decreased to RT over the 30-minute wash. Finally, the embryos were washed 
with 10-minute sequential incubations in 2:1, 1:1, and 1:2 SSCT/PBT. The embryos were 
then incubated in a blocking solution composed of fetal bovine serum, PBT, and bovine 
serum albumin for one to four hours at RT. Digoxigenin antibody (Thermo Fisher 
Scientific, Waltham, MA, USA) was added to the solution which was maintained at 4 ºC 
overnight. 
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On the third day, the embryos were washed using 15-minute duration sequential 
incubations of PBT and then added to 12-well plates with a staining buffer (5 mL Tris-
HCl, 2.5 mL MgCl2, 1.0 mL NaCl, 0.5 mL 0.1% Tween-20, deionized water). Quantities 
of 3.5 µL/mL of 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and 4.5 µL/mL of nitro 
blue tetrazolium (NBT) were added to the staining buffer to form the staining solution. 
The embryos and staining solution were covered to prevent light reaction and incubated 
in agitation at 37 ºC. They were checked every 20 minutes for staining and removed 
when the staining of the untreated condition matched the literature. Thus, the antibody 
was stained to show the presence of hemogenic endothelium markers in corresponding 
regions of the zebrafish. The embryos were stored at 4 ºC in 4% PFA overnight with 
Figure 4. Whole-mount in situ hybridization (WISH). Adult 
casper zebrafish were crossed, and progeny were treated with 
epigenetic candidate molecules prior to fixation in 4% 
paraformaldehyde (PFA) at 36, 48, 72, or 96 hpf. These fish were 
permeabilized with proteinase K and post-fixed again in 4% PFA. 
A four-hour pre-hybridization step was followed by overnight 
incubation with digoxigenin (DIG)-labeled RNA probes, which 
were made from linearized and purified plasmid from a cDNA 
library. cDNA = complementary DNA; DNA = deoxyribonucleic 
acid; RNA = ribonucleic acid. Procedure adapted from Amigo et 
al. (2009).  
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agitation. For long-term storage, the embryos were dehydrated using methanol and 
rehydrated with 4% PFA for imaging. Embryos were stored at 4 ºC until analysis. 
Stained embryos were imaged using the Leica DC 500 microscope and FireCam 
software (Leica Microsystems Inc., Buffalo Grove, IL, USA). Before the embryos were 
mounted in 90% glycerol for imaging, they were washed in a serial dilution with 90% 
glycerol to remove PFA. Expression of RNA was analyzed by scoring the staining as low 
medium, and high number of hemogenic events based on what constituted the majority of 
the embryos in the control.  
Time-Lapse Imaging of Endothelial-to-HSC Transition  
Epigenetic molecule-treated CD41:eGFPxFlk1MCherry  strain zebrafish were 
allowed to grow at 28 ºC for 24 hours. The treated embryos were dechorionated at 24 hpf 
with forceps, and the endothelial-to-HSC transition was measured overnight using a 
confocal microscope. Additional E3 medium containing the molecule was added. The 
embryos were anesthetized in 0.02% tricaine and mounted in 2% low-melt agarose to 
restrict their movement.  
Mouse Maintenance and Breeding  
C57BL/6J mice (The Jackson Laboratory) were bred according to the standards of 
Boston Children’s Hospital. Male and female mice were placed in cages overnight and 
allowed to breed. After 11.5 days, the mother was euthanized, and the embryos were 
removed for the colony-forming unit assay.  
Administration of Epigenetic Molecules to Mouse 
	 27	
Mouse embryos at 11.5 days (E11.5) were removed from the mother one at a time 
and placed in a solution of phosphate-buffered saline (PBS) and penicillin-streptomycin 
(Pen Strep). They were separated into glass vials (n = 1) with 35 µL 1 M glucose and 3.5 
mL fetal bovine serum (FBS) and then placed in a dark, rotating chamber at 30 rotations 
per minute at 37 ºC. A volume of 3.5 µL of 5.6 µM C646 dissolved in DMSO was added 
to each vial after 30 minutes, and the embryos were allowed to incubate overnight.  After 
approximately 30 hours (E12.5), the AGM of the embryo was removed for a colony-
forming unit assay. They were transferred into tubes with 10 µL elution buffer (EB 
buffer), incubated for 5 minutes, and then pipetted to break apart the tissue. After 
addition of 11 µL of FBS, they were incubated at 37 ºC for 5 minutes in order to 
inactivate the collagenase and hyaluronidase. One mL PBS was added, and the mixture 
was centrifuged at 300 x g for 4 minutes at 4 ºC. The cells were resuspended in 200 µL of 
sterile PBS and Pen Strep. The cells were then plated into colony-forming unit (CFU) 
media, and 200 µL of the cell suspension was added into one 3 mL CFU vial. This was 
mixed well with a needle and syringe, and the solution was plated onto 9 x 50 mm Petri 
dishes and placed for seven days at 37 ºC with 5% carbon dioxide using MethoCult™ 
H4034 Optimum kit from STEMCELL Technologies Inc. (Cambridge, MA, USA).  
Colony-Forming Unit Assay  
The number of hematopoietic CFUs from each single-cell suspension was counted 
on the seventh day. The colonies were categorized as CFU-GEMM (colony-forming unit-
granulocyte, erythrocyte, macrophage, megakaryocyte), CFU-GM (colony-forming unit-
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granulocyte, macrophage), BFU-E (burst-forming unit-erythroid), CFU-M (colony-
forming unit-macrophage), and CFU-G (colony-forming unit-granulocyte).  
  
Figure 5. Colony-forming unit assay. Colonies were categorized as (A) BFU-E 
(erythrocyte lineage), (B) CFU-GM (monoblasts and myeloblasts), (C) CFU-M (left, 
monocyte) and CFU-G (right, granulocyte), and (D) CFU-GEMM (multipotent stem 
cell). Image adapted from STEMCELL Technologies Inc. (citation?)  
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RESULTS 
 
Candidate Screen 
 The candidate molecules targeting epigenetic writers showed increased expression 
of c-myb and runx1 markers in the AGM of 36 hpf zebrafish (Figure 6). Compared with 
the control, C646 (1.6 µM, HAT inhibitor) and OICR9429 (1 µM, WDR5 inhibitor) 
significantly increased the expression of these markers in the AGM region (Figures 6A 
and 6D, respectively). Molecules which targeted epigenetic readers (bromodomains) 
showed an increase in c-myb and runx1 expression compared with the control (Figure 9). 
Molecules targeting epigenetic erasers (vorinostat, Ex-527, and JIB-04) varied in their 
results (Figure 7). Vorinostat (10 µM, HDAC inhibitor) decreased expression of c-myb 
and runx1 in the AGM region compared with the control (Figure 7A), whereas Ex-527 
(50 µM, Sirt1 inhibitor) and JIB-04 (0.1µM, JmJ inhibitor) increased c-myb and runx1 in 
the AGM region of 36 hpf zebrafish compared with the control (Figures 7B and 7C, 
respectively). A366, I-BET, and cyproheptadine proved toxic at all doses administered 
and all require further testing. Entinostat (Figure 8) decreased the amount of hemoglobin 
formed in the embryo at 48 hpf. UNC1215 (Figure 9) showed an increase in the 
expression of c-myb and runx1.  
 Of those molecules which increased c-myb and runx1 expression in the AGM, 
HAT inhibitor C646 showed the largest increase in high levels of expression compared 
with the control. Thus, further exploration was warranted regarding the effect of this 
molecule on the marker lmo2, required for yolk sac erythropoiesis (Warren et al., 1994), 
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the marker ikaros, required for differentiation into the hematopoietic lineages (Davis, 
2011), and the blood lineage markers, mpo and globin.  
HAT inhibitor treatment increases HSC formation in zebrafish and mouse 
Treatment with C646 (1.6 µM, HAT inhibitor) increased the expression levels of 
lmo2 and ikaros in 36 hpf zebrafish embryos compared with the control (Figure 10A). 
This same C646 treatment showed increased levels of the lineage marker globin, which 
indicates synthesis of hemoglobin, in 48 hpf embryos compared with the control (Figure 
10B). Also in 48 hpf embryos, the C646 treatment showed a much smaller increase for 
the mpo marker, which indicates the presence of monocytes (Figure 10C). Additionally, 
treatment with C646 increased the number of endothelial-to-hematopoietic transition 
events in the embryo (Figure 11).  
 In the mouse model at E11.5-E12.5, treatment with 1.6 µM C646 increased the 
total number of colony-forming units (CFUs) in the AGM of the embryo. In particular, 
the number of G (granulocyte) colonies increased (Figure 12).  
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Figure 6. Compounds which inhibit epigenetic writers increase expression of HSC 
markers c-myb and runx1 in 36 hpf zebrafish. Doses were optimized on a 
recommended assay concentration based on IC50 in cell lines. Expression was categorized 
as low, medium, or high in the AGM region. (A) C646 (HAT inhibitor, n = 84) and (D) 
OICR9429 (WDR5 inhibitor, n = 37) increased the number of high-staining embryos 
significantly compared with the control. (B) UNC0638 (G9a inhibitor, n = 91) and (C) 5-
azacytidine (DNMT inhibitor, n = 93) caused more modest increases in the number of 
high-staining embryos compared with the control. AGM = aorta-gonad-mesonephros; 
DNMT = DNA methyltransferase; HAT = histone acetyltransferase; hpf = hours 
postfertilization; HSC = hematopoietic stem cell; IC50 = concentration where response is 
reduced by half.   
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Figure 7. Compounds which inhibit epigenetic erasers regulate expression of HSC 
markers c-myb and runx1 in 36 hpf zebrafish. Doses were optimized on a 
recommended assay concentration based on IC50 in cell lines. Expression was categorized 
as low, medium, or high in the AGM region. (A) Vorinostat (general HDAC inhibitor, n 
= 60) increased the number of low-staining embryos compared with the control, whereas 
(B) Ex-527 (Sirt1 inhibitor, n = 39) and (C) JIB-04 (JmJ inhibitor, n = 108) increased the 
number of high-staining embryos compared with the control. AGM = aorta-gonad-
mesonephros; HDAC = histone deacetylase; hpf = hours postfertilization; HSC = 
hematopoietic stem cell; IC50 = concentration where response is reduced by half.   
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Figure 8. HDAC inhibitors decrease HSC formation in casper zebrafish. Entinostat 
(class I HDAC inhibitor, n = 65) increased the number of low-staining embryos for the 
globin marker, which indicates the presence of hemoglobin.  
 
 
 
	 34	
 
Figure 9. Compounds which inhibit epigenetic readers show no change in expression 
of HSC markers c-myb and runx1 in 36 hpf zebrafish. Doses were optimized on a 
recommended assay concentration based on IC50 in cell lines. Expression was categorized 
as low, medium, or high in the AGM region. UNC1215 (bromodomain inhibitor, n = 33) 
caused a decrease in the number of low-staining embryos in the AGM compared with the 
control. AGM = aorta-gonad-mesonephros; hpf = hours postfertilization; HSC = 
hematopoietic stem cell; IC50 = concentration where response is reduced by half.   
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Figure 10. C646 increases HSC formation in casper zebrafish. Embryos were treated 
with 1.6 µM of C646 (HAT inhibitor). (A) C646 treatment (n = 48) increased the number 
of high-staining embryos expressing the markers lmo2 and ikaros in 36 hpf zebrafish 
compared with the control. (B) C646 treatment (n = 64) increased the number of high-
staining embryos expressing the marker globin (which indicates the presence of 
hemoglobin) in 48 hpf zebrafish compared with the control. (C) C646 treatment (n = 58) 
showed a small increase in high-staining embryos and a decrease in low-staining embryos 
expressing the marker mpo (which indicates the presence of monocytes) in 48 hpf 
zebrafish compared with the control. HAT = histone acetyltransferase; hpf = hours 
postfertilization; HSC = hematopoietic stem cell. 
 
 
 
 
 
 
 
 
 
 
 
 
	 36	
  
  
  
 
(a)                                                                     (b) 
Figure 11:  C646 increases number of of cd41: eGFP+ HSCs emerging 
from endothelium of 24-36 hpf zebrafish. C646 treated embryos showed 20 
endothelial-to-HSC transition events compared to a mean of 10 events in the control. 
Events were determined when cells turned from hemogenic endothelium (red) to HSC 
(yellow, then green).   SD = 4.04. HSC = hematopoietic stem cell.  
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Figure 12. C646 increases HSC formation in E11.5-E12.5 mouse. C646 (1.6 µM, HAT 
inhibitor)-treated mouse showed an increase in total colony-forming units (CFUs) in the 
AGM after eight days in a single-cell suspension following treatment with the molecule 
overnight. In particular, there was a sharp increase in the number of G (granulocyte) 
colonies. The number of GEMM colonies increased from zero in the control to 9 in the 
embryo treated with C646. n = 1; P = 0.004 (T-test). See Methods section for additional 
description of the categories in the colony-forming unit assay. AGM = aorta-gonad-
mesonephros; E = embryonic day; HAT = histone acetyltransferase; HSC = 
hematopoietic stem cell. GEMM = granulocyte, erythrocyte, macrophage, 
megakaryocyte.  
  
C646 
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DISCUSSION 
The influence of epigenetic regulation in hematopoietic stem cell development is 
a promising field that has uses in the therapies for many blood-related disorders, 
including cancers like leukemia (Wouters and Delwel, 2016). The full potential of these 
epigenetic modulators remains to be explored, but many promising candidates have 
emerged as modulators for the endothelial-to-HSC transition during development and 
beyond. This transition represents the change of hemogenic endothelium in the aorta-
gonad-mesonephros (AGM) region of the organism (one of the first sites of 
hematopoiesis) to the multilineage HSCs/progenitors responsible for definitive 
hematopoiesis (Hirschi, 2012). Because of the inherent reversibility of epigenetic changes 
(Wouters and Delwel, 2016), controlling epigenetic modulators may allow the adjustment 
of dysregulation in pathways of blood pathologies or the treatment of them through HSC 
transplantation. The full therapeutic potential of these epigenetic modulators can only be 
realized through more understanding of their effects on HSC formation. There is a critical 
need for more exploration of the role of epigenetics in the development of hematopoietic 
stem cells. In particular, a functional assay (which is currently not available) is essential 
for the further illumination of these mechanisms. 
 The problem of assay availability was addressed by this study, in which an 
unbiased chemical screen of three different molecular classes—readers, writers, and 
erasers—was conducted, and increases or decreases in the expression of HSC-related 
markers were observed (Figure 13). These findings established a platform on which to 
build an understanding of epigenetic regulation of HSC development. In addition, the 
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unbiased chemical screen was established in the zebrafish, a model organism in which 
these changes can be observed clearly.  
In this study, epigenetic molecules were found to regulate the endothelial-to-HSC 
transition. Although a few links were established between epigenetic control and 
hematopoiesis (Hu and Shilatifard, 2016), these relations need to be clarified and 
explored further. 
Moreover, the observations from this study demonstrated two distinct outcomes. 
Molecules targeting epigenetic writers HAT, DNMT, G9a, and WDR5 increased 
expression of c-myb and runx1, indicating increased hematopoiesis. Of these molecules, 
HAT inhibition showed the largest increase in HSC development (Figure 11). Inhibition 
of HDAC through the drugs vorinostat and entinostat caused a significant decrease in 
HSC formation (Figure 7).  
	 40	
 
 
Figure 13. Summary of current findings from the zebrafish and mouse models. HAT 
= histone acetyltransferase; HDAC = histone deacetylase; HSC = hematopoietic stem 
cell. 
  
CONCLUSIONS 
 In this study, new small molecules were identified that regulate endothelial-to-
HSC transition. Of the molecules tested, those that targeted epigenetic writers, including 
C646 (HAT inhibitor), OICR9429 (WDR5 inhibitor), UNC0638 (G9a inhibitor), and 5-
azacytidine (DNMT inhibitor), were found to increase HSC formation in zebrafish. Ex-
527(Sirt1 inhibitor) and JIB-04(JmJ inhibitor), both erasers, also increased HSC 
formation, whereas the HDAC inhibitors, vorinostat and entinostat, decreased HSC 
formation. Other studies have shown that WDR5 can be a component of HAT complexes 
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(Guccione et al., 2007) and that  DNMT1 and G9a can interact to coordinate DNA and 
histone methylation during DNA replication (Esteve et al., 2006), and DNMT3 and G9a 
can collaborate in tissue differentiation in the zebrafish model (Rai et al., 2000). As HAT 
and WDR5 may work cooperatively, as well as DNMT and G9a, it follows that their 
inhibition would create the same effect on HSC formation. However, whereas histone 
acetylation is associated with the presence of euchromatin and increased transcription, 
DNA methylation is associated with heterochromatin and decreased transcription. 
Although these two have seemingly opposite effects, they both stimulate increases in 
HSC formation.  
Future Directions 
 There are many ways to expand this study. The HAT and HDAC inhibitors that 
increased and decreased HSC formation, respectively, should be explored in depth. There 
may be a worthwhile course of study in exploring the functional link between the two in 
the development of HSCs. Additionally, the similar effects of HAT/WDR5 and 
DNMT/G9a inhibition warrant further study. If two of these inhibitors were administered 
together in the zebrafish model, their seemingly opposite mechanisms could reveal that 
there are other factors at play. Similarly, DNMT/G9a inhibition has been shown to be 
cooperative in both DNA replication and different tissue expression in zebrafish, so it 
would be worthwhile to see whether they have cooperative effects in HSC formation. 
This could be achieved simply by combining the two molecules and administering them 
to the zebrafish.  
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In addition, the significant increase in G colonies after administration of a HAT 
inhibitor to the mouse indicates a specific increase in the formation of granulocytes at this 
stage. However, at the E11.5 stage, HSCs have already formed, and thus the HAT 
inhibitor should also be administered at the E10.5 time point to explore its effects at that 
stage. 
Furthermore, it is important to note that no compounds targeting epigenetic 
readers had any effect on HSC formation. Because only bromodomain inhibitors were 
tested, it is worthwhile to question whether other epigenetic readers would affect HSC 
formation or different classes of bromodomain inhibitors at higher doses. Rodriguez et al. 
(2014) reported that disruption of bromodomain and extra-terminal (BET) protein BRD4, 
a transcriptional regulator, causes reduced formation of hemogenic endothelium. This 
result suggests that the protein has an important role in the formation of hemogenic 
endothelium, and the mechanism should be clarified through further study.  
In summary, although HAT and other epigenetic writers, together with epigenetic 
erasers like HDAC, have emerged as promising targets for epigenetic therapies, the 
specifics of what molecules to target, as well as the role of other epigenetic modulators, 
remain to be discovered. 
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